AT1 FY21 - General Discussion + FA, page-626

COVID-19 Business Performance (FY20)
FY20 sales revenue of $5.4m
•COVID-19 Sales Revenue - $3.4m
NON-COVID Sales=$2m (assuming 500k in each quarter)
•COVID-19 Units Sold – 1.08m
3.4/1.08=$3.15 per device

NG Biotech (France) – high margin OEM contract for France and UK, 1.75m devices ordered to date (FY20)
If I interpreted correctly, the other 670k (1.75m-1.08m) devices sale were made in FY21
which is 670k*$3.15= $ 2.11m

Access Bio has placed an initial order for 259,200 Atomo devices to be used to build inventory of COVID-19 antibody tests in anticipation of US FDA approval.

DIVOC Labs has committed to an initial order of 77,000 units which will become effective upon receipt by DIVOC of regulatory approval of the product for professional use in India.

259200+77000=336200 devices in total* $3.15 = 1.059 m

Given the first quarter, AT1's sales were 2.5m and assuming the orders above turned into sales in the first two quarters.

The minimum amount of sales estimated for Q2 from the given data should be:
$ 2.11m + $1.059 m +$1.0m from Non-COVID side of business (assuming it is same as last year) - $2.5m from Q1 = $1.669m

There are a few other things I would like to know,
Has NG-biotech ordered more from us this quarter? If not, why not given the circumstances in Europe.
Has the other side of the business grown from last year? If so, how much? (given TGA approval for HIV tests, John also said in an interview that the HIV side of the business is doing better. And the success of AT1's partner Lumos)
Has AT1 applied for regulatory approval in SE Asian countries and Brazil? (if I remembered correctly) as they have the exclusive right to sell antibody tests.


PLEASE CORRECT ME IF I'M WRONG, as I do not have any experience in calculating this sort of stuff.

Cheers